These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 33894673

  • 1. Synergistic effects of α-Mangostin and sorafenib in hepatocellular carcinoma: New insights into α-mangostin cytotoxicity.
    Wang TT, Hong YF, Chen ZH, Wu DH, Li Y, Wu XY, Huang HQ, Zhang Q, Jia CC.
    Biochem Biophys Res Commun; 2021 Jun 18; 558():14-21. PubMed ID: 33894673
    [Abstract] [Full Text] [Related]

  • 2. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
    Wang L, Zhan Y, Wu Z, Lin M, Jin X, Jiang L, Qiu Y.
    Biomed Pharmacother; 2020 May 18; 125():110033. PubMed ID: 32187962
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Synergistic antitumor activity of sorafenib and artesunate in hepatocellular carcinoma cells.
    Yao X, Zhao CR, Yin H, Wang K, Gao JJ.
    Acta Pharmacol Sin; 2020 Dec 18; 41(12):1609-1620. PubMed ID: 32300243
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line.
    Wang W, Xu B, Li Q, Jiang D, Yan S.
    Mol Med Rep; 2018 Apr 18; 17(4):6185-6193. PubMed ID: 29484394
    [Abstract] [Full Text] [Related]

  • 8. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
    Gedaly R, Angulo P, Chen C, Creasy KT, Spear BT, Hundley J, Daily MF, Shah M, Evers BM.
    Anticancer Res; 2012 Jul 18; 32(7):2531-6. PubMed ID: 22753710
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway.
    Tan W, Zhu S, Cao J, Zhang L, Li W, Liu K, Zhong J, Shang C, Chen Y.
    Oncol Res; 2017 Nov 02; 25(9):1543-1553. PubMed ID: 28276313
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Ropivacaine synergizes with sorafenib to induce apoptosis of hepatocellular carcinoma cells via the IL-6/STAT3 pathway.
    Wang W, Lin H, Liu D, Wang T, Zhu Z, Yu P, Zhang J.
    Cancer Sci; 2024 Sep 02; 115(9):2923-2930. PubMed ID: 39014520
    [Abstract] [Full Text] [Related]

  • 18. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
    Wang H, Zhang C, Chi H, Meng Z.
    Int J Oncol; 2018 Jun 02; 52(6):2051-2060. PubMed ID: 29620259
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.